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Abstract
Introduction: Stimulating the commitment of implanted dystrophin+ muscle-derived stem cells (MDSCs) into
myogenic, as opposed to lipofibrogenic lineages, is a promising therapeutic strategy for Duchenne muscular
dystrophy (DMD).
Methods: To examine whether counteracting myostatin, a negative regulator of muscle mass and a pro-lipofibrotic
factor, would help this process, we compared the in vitro myogenic and fibrogenic capacity of MDSCs from wild-
type (WT) and myostatin knockout (Mst KO) mice under various modulators, the expression of key stem cell and
myogenic genes, and the capacity of these MDSCs to repair the injured gastrocnemius in aged dystrophic mdx
mice with exacerbated lipofibrosis.
Results: Surprisingly, the potent in vitro myotube formation by WT MDSCs was refractory to modulators of
myostatin expression or activity, and the Mst KO MDSCs failed to form myotubes under various conditions, despite
both MDSC expressing Oct 4 and various stem cell genes and differentiating into nonmyogenic lineages. The
genetic inactivation of myostatin in MDSCs was associated with silencing of critical genes for early myogenesis
(Actc1, Acta1, and MyoD). WT MDSCs implanted into the injured gastrocnemius of aged mdx mice significantly
improved myofiber repair and reduced fat deposition and, to a lesser extent, fibrosis. In contrast to their in vitro
behavior, Mst KO MDSCs in vivo also significantly improved myofiber repair, but had few effects on lipofibrotic
degeneration.
Conclusions: Although WT MDSCs are very myogenic in culture and stimulate muscle repair after injury in the
aged mdx mouse, myostatin genetic inactivation blocks myotube formation in vitro, but the myogenic capacity is
recovered in vivo under the influence of the myostatin+ host-tissue environment, presumably by reactivation of
key genes originally silenced in the Mst KO MDSCs.
Introduction
The lipofibrotic degeneration of skeletal muscle (that is,
excessive deposition of endomysial collagen, other extra-
cellular matrix, and fat), characterizes muscle dystrophy,
and in particular Duchenne muscular dystrophy (DMD)
[1,2], as seen also in its animal model, the mdx mouse
[3-5]. This process, associated with inflammation and oxi-
dative stress [6], is partially responsible for the severe mus-
cle contractile dysfunction in DMD and the mdx mouse,
caused mainly by the bouts of myofiber necrosis due to
dystrophin genetic inactivation. In the gastrocnemius,
these processes are rather mild in young animals but
become particularly severe after 8 to 10 months of age [4].
Dystrophic muscle fibrosis not only is a major factor for
DMD mortality, but also hampers the uptake and survival
of cells implanted for potential therapeutic approaches [7]
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and/or may drive their differentiation into myofibroblasts
[4]. Therefore, trying to ameliorate this process while sti-
mulating myogenesis constitutes an ancillary strategy to
favor repair and regeneration of dystrophic muscle tissue,
even under ineffective or absent dystrophin replacement.
Although pharmacologic approaches to combat mus-
cle lipofibrotic degeneration and the underlying chronic
inflammation are being widely investigated, biologic fac-
tors such as myostatin, the main negative regulator of
muscle mass [8], are also potential key targets. Myosta-
tin, a member of the TGF-b family, aggravates muscle
dystrophy not only as an antimyogenic agent but also as
a profibrotic and adipogenic factor [9-14]. Inhibition of
myostatin by using its propeptide, shRNA, or specific
antibodies, improves myogenesis and reduces fibrosis in
the mdx mouse [15-17] and also in the rat [18]. The
same effects are generated in response to genetic dele-
tion of myostatin in the myostatin knockout (MST KO)
mouse, in which myofiber hypertrophy is associated
with less fat and reduced fibrosis [19-23].
It is assumed that in the dystrophic or injured muscle,
tissue repair and the opposite process of lipofibrotic
degeneration involve not only the differentiation of pro-
genitor satellite cells and fibroblasts into myofibers and
myofibroblasts, respectively, but also the modulation of
lineage commitment by stem cells present in the adult
muscle [24-26]. These stem cells have been isolated from
the rodent and human skeletal muscle and named, in gen-
eral, muscle-derived stem cells (MDSCs), because they
have the ability to differentiate in vitro into multiple cell
lineages and to generate myofibers, osteoblasts, cardio-
myocytes, or smooth muscle cells after implantation into
the skeletal muscle, bone, heart, corpora cavernosa, or
vagina, respectively [27-31]. They are not satellite cells and
may act also by secreting paracrine growth factors that are
believed to modulate the differentiation of endogenous
stem cells or the survival of differentiated cells in the tis-
sue [32-34]. However, the roles of MDSCs in the biology
and pathophysiology of the skeletal muscle are largely
unknown.
Myostatin modulates the differentiation of pluripotent
cells in vitro, albeit in some cases, with conflicting out-
comes [14,35-37]. It also inhibits the proliferation and
early differentiation of both satellite cells from the skeletal
muscle and cultured myoblasts, and blocking its expres-
sion improves the success of their in vivo transplantation
[38-40]. To our knowledge, no reports are available on
myostatin effects on MDSC differentiation, either in vitro
or in the context of repairing the exacerbated lipofibrosis
in the injured muscle of aged mdx mice.
MDSCs obtained from wild-type (WT) mice have
been tested experimentally, aiming to trigger repair of
the mdx muscle with variable results [31-45], but they
appear to be superior in this respect to myoblasts or
satellite cells [46]. However, some of the main limita-
tions of myoblast therapy, when translated from the
murine models into DMD and other human muscle dys-
trophies, may also affect the MDSCs and other types of
stem cells [47]. Therefore, it is a therapeutic goal to
enhance the repair capacity of WT MDSCs by in vitro
or in vivo modulation of their multilineage potential,
and to stimulate or even awake endogenous stem cells
of dystrophic muscle to regenerate myofibers while
avoiding differentiation into cells responsible for lipofi-
brotic degeneration. Such an approach may be provided
by the use of MDSCs where myostatin is genetically
inactivated (that is, obtained from the Mst KO mouse),
under the assumption that myogenesis would be stimu-
lated and the undesired lineage commitment reduced,
even when implanted into a host tissue environment
with normal myostatin expression. No reports are avail-
able on the in vitro and in vivo differentiation of these
MDSCs and how this affects, even paracrinely, muscle
repair.
Potential in vitro modulation of MDSCs, or the effects
that myostatin or dystrophin gene inactivation exert on
this balance
In the current study, we have investigated the in vitro
myogenic versus fibrogenic and adipogenic differentiation
of Mst KO MDSCs vis-à-vis the WT counterpart, and the
effects of manipulation of these processes by modulating
myostatin expression or activity, and by other putative reg-
ulators of muscle mass and fibrosis. Their differential in
vitro features in terms of the expression of some key stem
cell and myogenic genes, and the repair ability of Mst KO
MDSCs in the injured mdx muscle, also were studied. The
ultimate goal is to gain a preliminary insight into how in
vitro preconditioning of MDSCs by pharmacologic or
gain-of-function approaches may modulate their capacity
to repair dystrophic skeletal muscle, to design in vivo
pharmacologic interventions that may mimic these
processes, and even myostatin blockade in the host muscle




Mst knockout mice (C57BL/6J/Mst-/-), referred to here as
Mst KO, are regularly maintained and bred in our vivar-
ium on a BL/6 background [48], derived from the original
strain on a Balb/c background. Aged-matched wild-type
control mice (C57BL/6J), referred to here as WT, were
from Jackson Laboratories (Bar Harbor, ME, USA). Hin-
dlimb muscles from the WT and Mst KO male mice (12
to 16 weeks old) were subjected to the preplating proce-
dure to isolate MDSCs [49,50], by using a modification of
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a well-validated method that has led to extensively charac-
terized stem cell populations [5,27-30,46,49]. Tissues were
dissociated by using sequentially collagenase XI, dispase II,
and trypsin, and after filtration through 60-μm nylon mesh
and pelleting, the cells were suspended in plating medium
(PM), containing Dulbecco Modified Eagle Medium
(DMEM), with 10% fetal bovine serum (FBS), 10% horse
serum, and 0.5% chick embryo extract (US Biological,
Marblehead, MA, USA). Cells were plated onto collagen I-
coated flasks for 1 hour (preplate 1 or pP1), and 2 hours
(preplate 2 for pP2), followed by sequential daily transfers
of nonadherent cells and replatings for 2 to 6 days, until
preplate 6 (pP6). The latter is the cell population contain-
ing MDSCs. Sca1+ cells were selected with immunobeads
(Milteni, Auburn, CA, USA) coated with antibody against
Sca1 as small cells with a large nucleus that easily form
clusters/spheroids [24-27]. Cells were subjected to flow
cytometry, as described later, for the MDSC standard mar-
kers Sca1, CD34, and CD44, and for the key stem-cell
gene, Oct 4 [43], maintained in growth medium (GM)
GM-20 (DMEM, with 20% FBS) on regular culture flasks
(no coating) and used in passages 14 to 28. WT MDSCs
have been maintained in our laboratory for at least 40
generations with the same, or even increasing, growth rate.
Flow cytometry
MDSC and KO cells were grown in GM-20, washed twice
with Hanks, disaggregated by repeated pipetting in Cell
Stripper (Mediatech, Manassas, VA, USA), pelleted, and
resuspended in staining buffer consisting of PBS, 3% FBS,
0.01% Na azide (SB). Cells were incubated in the presence
of antibodies for 30 minutes on ice, washed twice with SB,
and finally resuspended in SB for flow cytometry on an
LSR II (BD Biosciences, San Jose, CA, USA). Data analysis
and plotting were done by using FACSDiva Version 6.1.1
software. All fluorophore-conjugated antibodies and iso-
type controls were from eBioscience (San Diego, CA,
USA), as follows: CD44-APC-eFluor 780; CD34-eFluor
660; Sca1-PE; Oct 4-PE (performed separately, after cell
permeabilization with BD CytoFix/CytoPerm Kit), and the
appropriate rat isotype controls IgG2b-APC-eFluor 780,
IgG2a-eFluor 660, and IgG2a-PE. BD CompBeads (rat)
were used for compensation.
Stem cell characterization, differentiation, and
modulation
MDSC cultures were analyzed for the expression of stem
cell markers, as described later, on collagen-coated six-
well plates and eight removable-chamber plates. Multipo-
tency was analyzed in 2-week incubations with GM-20 or
GM-10 (GM with 10% FBS) supplemented or not with 10
nM DMSO or 5 ng/ml TGF-b1, or, to induce myofiber
formation, after reaching confluence, for 2 to 3 weeks with
GM-HC (DMEM, 10% FBS, 5% horse serum, and 50 μm
hydrocortisone to promote proliferation, a key event in
myogenic differentiation) [44,45], or as described. In
certain cases, cultures were treated with or without 20 μM
5’-azacytidine (AZCT) in GM-20 for 3 days to induce mul-
tipotency, before switching them to the appropriate
medium [11,14,51].
For the tests on the modulation of MDSCs skeletal
myotube formation by various factors, cells were allowed
to reach confluence, switched to GM-HC, and incubated
for 2 weeks with 2 μg/ml recombinant 113-amino acid
myostatin protein (R-Mst), a biologically active recombi-
nant 16-kDa protein containing 113 amino acid residues
of the processed human myostatin protein (BioVendor
Laboratory Medicine Inc., Palackeho, Czech Republic)
[14,52,53], or with a recombinant mouse follistatin protein
(RD Systems, Minneapolis, MN, USA) at 0.2 μg/ml
[11,14], changing medium twice a week. In other experi-
ments, incubations with the monoclonal (Chemicon Inter-
national, Temecula, CA, USA) and polyclonal (Millipore
Corp, Billerica, MA, USA) antibodies against myostatin
(1:20) were substituted for the previous treatments. Alter-
natively, the adenoviruses expressing the mouse myostatin
full-length cDNA under the CMV promoter (AdV-CMV-
Mst375) and an shRNA, which targets myostatin RNA
and inhibits more than 95% of myostatin gene expression
[11,14,18] (AdV-Mst shRNA) were transduced into
MDSCs at 80% confluence. Then cells were switched to
GM-HC medium, as described earlier.
Implantation of MDSCs into skeletal muscle
Male mdx mice (C57BL/6/10ScSn-Dmdmdx), referred to
here as “mdx”, obtained from Jackson Laboratories (Bar
Harbor, ME, USA) were allowed to reach 10 months of
age, to allow lipofibrotic degeneration to become more
evident, not only in the diaphragm but also in the gastro-
cnemius. In contrast, in young animals (12 to 16 weeks of
age), the first round of muscle necrosis and regeneration
had already subsided (stable phase).
Mice were treated according to National Institutes of
Health (NIH) regulations with an Institutional Animal
Care and Use Committee-approved protocol. In one
experiment, the WT and mdx MDSCs (0.5 to 1.0 × 106
cells/50 μl saline) were labeled with the nuclear fluores-
cent stain, 4’,6-diamidino-2-phenylindole (DAPI) [27-30],
and implanted aseptically under anesthesia into the surgi-
cally exposed tibialis anterior. The muscle had been
cryoinjured by pinching it for 10 seconds with a forceps
cooled in liquid nitrogen immediately before implantation.
Control mice with the same cryoinjury received saline.
Mice were killed after 2 weeks, and the tibialis excised and
subjected to cryoprotection in 30% sucrose, embedding in
OCT, and cryosectioning.
In another experiment, the DAPI-labeled WT and Mst
KO MDSCs (0.5 × 106 cells/50 μl GM) were implanted
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into the central region of the surgically exposed left gas-
trocnemius of 10-month-old mdx mice, which 4 days
earlier had been injured with two injections of notexin
in both tips of the muscle (total: 0.2 μg in 10 μl saline).
Control muscle-injured mice were injected with saline
(n = 5/group). Mice were killed at 3 weeks, the gastro-
cnemius excised, and a section around the site of
notexin injection was used for cryosectioning. The
remaining tissue was kept frozen at -80°C.
Immunocytochemistry and dual immunofluorescence
Cells on collagen-coated eight-well removable chambers,
fixed in 2% p-formaldehyde, and 10 μm unfixed frozen
tissue sections, were reacted [10,11,14,18,29,30] with
some of the following primary antibodies against
(a) human myosin heavy-chain fast, detecting both
MHC-IIa and MHC-IIb); monoclonal, 1:200 Vector
Laboratories, Burlingame, CA, USA), a marker for skele-
tal myotubes and myofibers; (b) human ASMA (mouse
monoclonal in Sigma kit, 1:2, Sigma Chemical, St. Louis,
MO, USA), a marker for both SMCs and myofibroblasts;
(c) neurofilament 70 (NF70; mouse monoclonal, 1:10,
Millipore); (d) Dystrophin (rabbit polyclonal, 1:200
Abcam, Cambridge, Massachusetts, USA); (e) Sca-1
(mouse monoclonal, 1:100, BD Pharmingen, San Jose,
CA, USA) and M.O.M blocking kit (Vector, Burlingame,
CA, USA); and (f) Oct 4 (rabbit polyclonal, 1:500,
BioVision, Mountain View, CA, USA). When MDSCs in
eight-well chambers were not previously tagged with
DAPI, all nuclei were stained with coverslips with DAPI
antifading emulsion.
Cultures or tissue sections not involving DAPI labeling
were subjected to immunohistochemical detection by
quenching in 0.3% H2O2, blocking with goat (or corre-
sponding serum), and incubated overnight at 4°C with the
primary antibody. This was followed by biotinylated anti-
mouse IgG (Vector Laboratories), respectively, for 30
minutes, the ABC complex containing avidin-linked
horseradish peroxidase (1:100; Vector Laboratories), 3,3’
diaminobenzidine, and counterstaining with hematoxylin,
or no counterstaining. For cells labeled with DAPI, fluor-
escent detection techniques were used. The secondary
anti-mouse IgG antibody was biotinylated (goat, 1:200,
Vector Laboratories), and this complex was detected with
streptavidin-Texas Red. After washing with PBS, the sec-
tions were mounted with Prolong antifade (Molecular
Probes, Carlsbad, CA, USA). Negative controls in all cases
omitted the first antibodies or were replaced by IgG
isotype. In the case of Oct 4, streptavidin-FITC was used.
In tissue cryosections for experiments involving DAPI-
labeled cells (10 μm), tissue sections were processed in
regions where the DAPI+ cells could be detected. Muscle
fibers were either stained with hematoxylin/eosin, or by
MHC-II antibody, either by Texas red fluorescence as
previously described, or with the diaminobenzidine tetra-
hydrochloride-based detection method (Vectastain-Elite
ABC kit; Vector Labs), counterstaining with Harris
hematoxylin. Tissue sections that were incubated with
mouse IgG instead of the primary antibody served as
negative controls. The sections were viewed under an
Olympus BH2 fluorescent microscope, and cell cultures,
under an inverted microscope. In some cases, the cyto-
chemical staining was quantitated by image analysis by
using ImagePro-Plus 5.1 software (Media Cybernetics,
Silver Spring, MD, USA) coupled to a Leica digital micro-
scope bright-field light fluorescence microscope/VCC
video camera. After images were calibrated for back-
ground lighting, integrated optical density (IOD, area ×
average intensity) was calculated.
Gene transcriptional expression profiles
Pools of total cellular RNA from three T25 flasks for each
MDSC cultured in DM-20 were isolated with Trizol-
Reagent (Invitrogen, Grand Island, NY, USA) and subjected
to DNAse treatment, assessing RNA quality by agarose gel
electrophoresis. cDNA gene microarrays (SuperArray
BioScience Corp., Frederick, MD, USA) [11,24,41] were
applied, by using the mouse stem cell (OMM-405), Oligo
GEArray microarray. Biotin-labeled cDNA probes were
synthesized from total RNA, denatured, and hybridized
overnight at 60°C in GEHybridization solution to these
membranes. Chemiluminescent analysis was performed per
the manufacturer’s instructions. Raw data were analyzed by
using GEArray Expression Analysis Suite (SuperArray
BioScience Corp.). Expression values for each gene based
on spot intensity were subjected to background correction
and normalization with housekeeping genes, and then fold
changes in relative gene expression were calculated. Micro-
array data were deposited in the Gene Expression Omnibus
(GEO) public repository (accession number GSE28986).
The expression of some of the down- or upregulated
genes detected earlier was examined on 1 μg RNA iso-
lated from consecutive similar incubations performed in
triplicate by reverse transcription (RT) by using a 16-mer
oligo(dT) primer, as previously described [11,27], and the
resulting cDNA was amplified using PCR in a total
volume of 20 μl. The locations of the primers used for
the quantitative estimation of mouse myostatin mRNA
were nts 136 to 156 (forward) and 648 to 667 (reverse),
numbering from the translation initiation codon, as pre-
viously described. For mouse GAPDH primers, sequences
were from the mRNA sequence NM_008084.2, with a
forward primer spanning nts 778-797 and reverse primer
spanning nts 875-852, with a product length of 98 nt.
Additional primers were designed by using the NCBI
Primer Blast program applied to mRNA sequences and
synthesized by Sigma-Aldrich. Numbering refers to the
length in NT from the 5’ end of the mRNA: (a) Acta1
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(skeletal muscle actin) NM_009606.2 (forward 501 to
520 and reverse 841 to 822; product length, 341);
(b) Actc1 (cardiac actin) NM_009608.3 (forward 38 to
58 and reverse 554 to 530, product length 517);
(c) MyoD NM_010866.2 (forward 515 to 534 and
reverse 1013 to 994, product length 499); and (d) Pax3
NM_008781.4 (forward 1164 to 1183 and reverse 1893
to 1874, product length 730). The number of PCR cycles
used for each primer set is stated in parenthesis, as fol-
lows: Actc1 (30), Acta1 (30), MyoD1 (33), Pax3 (28),
and GAPDH (26). All primers were designed to include
an exon-exon junction in the forward primer, except for
GAPDH and MyoD1. Negative controls omitted cDNA.
Protein expression by Western blots
Cells were homogenized in boiling lysis buffer (1% SDS,
1 mM sodium orthovanadate, 10 mM Tris pH 7.4 and
protease inhibitors, followed by centrifugation at 16,000
g for 5 minutes [10,11,14,18,29,30]. Then 40 μg of pro-
tein was run on 7.5% or 10% polyacrylamide gels, and
submitted to transfer and immunodetection with antibo-
dies against (a) human ASMA (monoclonal, 1:1,000;
Calbiochem, Billerica, MA, USA); (b) Oct 4, as for
immunohistochemistry; (c) MyoD (rabbit polyclonal
1:200, Santa Cruz Biotechnology, Dallas, TX, USA); (d)
MHC (fast), as for immunohistochemistry; (e) TGF-b1
(rabbit polyclonal, 1:1,000; Promega Corporation, Madi-
son, WI, USA); (f) myostatin (rabbit polyclonal 1:1,000;
Chemicon International Inc), (g) ActRIIb (monoclonal,
1:1,000, Abcam); and (h) GAPDH (mouse monoclonal,
1:3,000, Chemicon). Membranes were incubated with
secondary polyclonal horse anti-mouse or anti-rabbit
IgG linked to horseradish peroxidase (1:2,000; BD
Transduction Laboratories, Franklin Lakes, NJ, USA, or
1:5,000, Amersham GE, Pittsburgh, PA, USA), and
bands were visualized with luminol (SuperSignal West
Pico; Chemiluminescent, Pierce, Rockford, IL, USA). For
the negative controls, the primary antibody was omitted.
Statistics
Values are expressed as the mean (SEM). The normality
distribution of the data was established by using the Wilk-
Shapiro test. Multiple comparisons were analyzed with a
single-factor ANOVA, followed by post hoc comparisons
with the Newman-Keuls test. Differences among groups
were considered statistically significant at P < 0.05.
Results
MDSC cultures from the Mst KO resemble their
counterparts from WT mice in morphology, replication,
cell markers, and multipotent differentiation
WT MDSCs (pP6 fraction) formed in vitro the most
robust skeletal myotubes (see next section) at about
passage 13, and WT MDSCs and Mst KO MDSCs were
compared from passages 10 through 28. The morphol-
ogy of the proliferating cultures was similar, but the
replication times for the Mst KO MDSCs were slower
than those for the WT MDSCs (27.0 versus 19.8 hours,
respectively). This morphology and replication pattern
continued throughout the 13- through 28-passages per-
iod of study.
The WT MDSC culture was previously shown to be
Sca1+ [28]; Sca1 selection was used for both cultures,
and flow cytometry confirmed its expression in subcon-
fluent cultures in DM-10 of both the WT and Mst KO
MDSCs (Figure 1A), with negligible isotype reaction.
The similarity of both types of cells was evident as well
for the expression of the two MDSC markers CD34,
CD44, and the key embryonic stem cell marker, Oct 4,
even if the cell populations show some heterogeneity in
the expression of these markers. Oct 4 in both MDSC
cultures is similarly well expressed, mainly in the nuclei
(the Oct 4A isoform) with some additional cytoplasmic
staining (Figure 1B). That MDSCs have some embryonic
stem cell features is also suggested by a mild alkaline
phosphatase reaction, a feature of embryonic stem cells
(Figure 1C).
The stem cell nature of the nuclear Oct 4A expression
was confirmed by the detection of the 45-kDa Oct 4A
transcriptionally active protein accompanied to a lesser
extent by the 33-kDa Oct 4B of cytoplasmic origin (Figure
1B bottom).
The similarity of the Mst KO and WT MDSCs in
terms of the expression of other stem cell-related genes
was demonstrated by a DNA microarray analysis of a
panel of 260 stem cell-related genes. Table 1 shows no
substantial differences in the expression of most well-
known embryonic stem cell genes, such as c-Myc, Oct 4
(Pou5), alkaline phosphatase 2 and 5, telomerase reverse
transcriptase, leukemia inhibitory factor (LIF), and mas-
termind-like 1, among the other related genes. This
agrees with the fact that MDSCs appear to undergo a
multilineage differentiation, and the capacity of these
MDSCs seems to be qualitatively similar, as shown by
the generation in neurogenic medium of cells expressing
the neuronal marker NF70 (Figure 2), and in fibrogenic
medium of cells expressing a-smooth muscle actin
(ASMA), suggesting some neural or myofibroblast dif-
ferentiation, respectively. However, the proportion of
positive cells was lower in Mst KO MDSCs, and the
cells expressing NF-70 lacked the more apparent neuro-
nal morphology of the differentiated WT MDSCs. Both
MDSC cultures also differentiated similarly into cells
expressing calponin as smooth muscle cell marker and
von Willebrand factor as endothelial cell marker (not
shown).
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The genetic inactivation of myostatin is, however,
associated with the loss of the ability of MDSCs to form
myotubes in vitro, and with the downregulation of key
myogenic genes
The WT MDSCs form large polynucleated myotubes
expressing MHC II in confluent cultures on incubation for
1 to 2 weeks in GM-HC (Figure 3A, B). This myogenic
medium [54,55] was selected based on its high efficiency
as reported for adipose tissue stem cells and on our own
preliminary results over a medium containing horse
serum. However, remarkably, the Mst KO MDSC (Figure
3C) were unable to generate any myotube under these
conditions, even after 4 weeks. Immunofluorescence
detected high MHC II expression in the robust myotubes
from WT MDSC (Figure 3D), but again, no MHC II or
myotubes were found in the Mst KO confluent cultures
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Figure 1 Effect of genetic inactivation of myostatin on the expression of key stem cell marker genes in MDSC. (A) Flow cytometry (no
gate) was conducted for Sca1 (red), CD34 (black), CD44 (green), and Oct 4 (blue) in WT MDSCs (blue) and Mst KO MDSCs (purple), against the
respective isotypes (not shown). Top panels: Left: WT MDSCs; Right: Mst KO MDSCs. Bottom panels: each antigen is compared separately for WT
(blue) and Mst KO (purple), with the corresponding isotypes (WT, dark gray; Mst KO, light gray). (B) Representative pictures of proliferating
MDSCs that were subjected to immunocytochemistry for Oct 4, showing nuclear location in most cells (200×). (C) Proliferating MDSCs that were
subjected to cytochemistry for alkaline phosphatase (200×). (D) Homogenates from the same cell cultures that were subjected to Western blot
for Oct 4 (nuclear Oct 4a, 45 kDa; cytoplasmic Oct 4 b, 33 kDa). WT, wild type; MDSC, muscle-derived stem cell; Mst KO, myostatin knockout.
Table 1 Some stem cell-related genes are transcribed
similarly in MDSCs, irrespective of myostatin inactivation
Gene Function WT KO
Myc Myelocytomatosis oncogene 12.4 18.1
Pou5F1 Pou domain (Oct4) 10.1 16.7
Akp 2 Alkaline phosphatase 2 6.4 6.9
Akp 5 Alkaline phosphatase 5 1.2 1.6
Tert Telomerase reverse transcriptase 1.0 1.0
Utf 1 Undifferentiated embryonic cell TP1 1.0 0.8
Man 1 Mastermind-like 1 13.1 16.7
Lif Leukemia inhibitory factor 1.5 0.9
PPARg Peroxisome proliferator-activated receptor g 1.1 1.8
RNA from the two MDSC types at 80% confluence (not undergoing
myogenesis) were treated by DNAse and submitted to DNA microarrays.
Some key stem cell genes are selected. Values are relative expression levels
normalized by housekeeping genes. GAPDH expression was 98 to 102. MDSC,
muscle-derived stem cell; WT, wild type; KO, myostatin knockout.
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analysis where the strong MHC II 210-kDa band in the
WT MDSC extract is not seen in the confluent Mst KO
MDSC (Figure 3E). The early myogenic marker MyoD is
expressed as expected in the nonconfluent WT MDSCs in
GM-20 (nonmyogenic medium), but very little in the Mst
KO MDSCs.
That this was not an artifact of poor myogenesis in the
GM-HC medium was shown by the fact that although
robust myotube formation in the WT MDSCs occurred in
GM-10 or GM-20, even if of smaller size (Figure 4B and
4C compared with Figure 4A), not a single myotube was
observed with confluent Mst KO MDSCs in these media
(not shown). WT MDSC myogenic differentiation in med-
ium with a high concentration of FBS indicates that cell-
to-cell contact is sufficient to trigger MDSC myogenesis,
and does not require growth-factor depletion. No adipo-
genesis was detected by Oil red O in GM-HC medium
(not shown). Western blots of parallel confluent cultures
of WT MDSCs showed that MHC-II was expressed in all
media (triplicate cultures), although more intensively in
GM-HC (Figure 4D). No difference in MyoD expression
was found among the different media.
Confluent Mst KO in several media were unable to form
myotubes irrespective of passage. Myotube formation by
WT MDSC cultures persisted for up to 40 passages,
although the size and number of the myotubes started to
decline as the passage number increased. Cultures of pP5
or pP5 from Mst KO mice obtained during the pre-plating
procedure also failed to generate skeletal myotubes.
Despite the drastic obliteration of MHC II+ myotube for-
mation in confluent Mst KO MDSCs, the transcriptional
expression of most myogenesis-related genes in the
respective proliferating cells was, as in the case of the stem
cell genes in Table 1, very similar. For instance, expression
of BMPRs (bone morphogenic protein receptors), the Wnt
signaling receptors frizzled and jag, IGF1, Notch 1, and
Notch 3, was not reduced in Mst KO MDSCs as compared






Figure 2 Myostatin genetic inactivation does not block the multipotent nonmyogenic differentiation capacity of MDSCs. Representative
pictures of proliferating MDSCs treated for 2 weeks in differentiation media and subjected to immunocytochemistry for NF-70 (A) and ASMA (B)
to detect marker expression of neural cells and myofibroblasts (200×). MDSC, muscle-derived stem cell; WT, wild type (muscle-derived stem cells);
KO, myostatin knockout (muscle-derived stem cells); ASMA, a-smooth muscle actin.
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differences were noticed in which each gene was substan-
tially downregulated in the Mst KO MDSCs, versus a
strong expression in the WT MDSCs. They are Spp1
(secreted phosphoprotein 1, or osteopontin), Actc 1 (car-
diac a-actin), MyoD1, cadherin 15, Myf 5, and Notch 2
(see Discussion). In contrast, other cadherins (11 and 6),
related to neuromuscular development, were upregulated
by ninefold and fourfold, respectively, in the Mst KO
MDSCs. Other than these, a virtual 98% similarity was
seen among the three MDSC types, in terms of the 260
genes investigated. An excellent correlation occurred
between MyoD mRNA expression in both cultures and
the previously detected MyoD protein levels shown in
Figure 3.
These results were corroborated by RT-PCR for some











WT     KO
MyoD
WT             KOF
Figure 3 Myostatin genetic inactivation blocks the myogenic differentiation capacity of MDSCs. (A-C) Representative pictures of
confluent MDSCs from the WT MDSCs and Mst KOs maintained for 2 weeks in myogenic medium and subjected to immunocytochemistry for
MHC II to detect differentiation into polynucleated myotubes (magnifications as indicated). (D) Blue/red merge of confluent MDSCs in myogenic
medium that were labeled with DAPI and submitted to immunofluorescent detection of MHC (200×); (E) Western blot for MHC II (210 kDa) in
the confluent cultures undergoing myogenesis, and (F) for MyoD (45 kDa) in the nonconfluent cultures in nonmyogenic medium. MDSC,
muscle-derived stem cell; WT, wild type; Mst KO, myostatin knockout; MHC, myosin heavy chain; DAPI: 4’, 6-diaminido-phenylindole.
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the gel electrophoretic pattern after staining with ethi-
dium bromide, and Figure 5B presents the densitometric
value of each band from triplicate determinations cor-
rected by the housekeeping-gene values. These ratios
are comparable between both MDSC cultures for each
gene, but not among the different genes for each cul-
ture, because of the different numbers of cycles applied
for the respective transcript amplification. Actc1, Acta1,
and MyoD are significantly downregulated in Mst KO as
compared with WT MDSCs, and Pax 3 is overex-
pressed, in good agreement with the DNA microarrays.
Myotube formation cannot be induced in Mst KO MDSCs
by stem cell-reactivating agents, and the WT MDSCs are
also refractory to positive or negative modulation of
myostatin expression
Incubation of Mst KO MDSCs for 3 days with 5-azacyti-
dine, a demethylating agent and potent inducer of myo-
genic capacity in pluripotent cell lines [11,14], before
their reaching confluency and switching to myogenic
medium, failed to induce myotube formation, but it also
failed to stimulate it in the WT MDSCs (not shown).
Follistatin, which should upregulate myotube formation
by binding myostatin, was also virtually ineffective on
WT MDSCs, and the same resistance to modulation
was observed under recombinant myostatin, which
should exert the opposite effects. Figure 6A through D
shows that the area occupied by MHC II+ myotubes was
not reduced in the cultures treated from the start of
myotube induction with 2 μg/ml myostatin (Figure 6B),
or increased by 0.5 μg/ml follistatin (Figure 6C), as com-
pared with untreated controls (Figure 6A). Changes
were not significant (Figure 6D). This failure of myosta-
tin and follistatin to affect myogenesis in any type of
MDSCs occurred despite these cells expressing the
myostatin receptor ActRIIb in both cultures as shown
by Western blot (Figure 6E), implying that they should
be responsive to exogenous myostatin. Endogenous
myostatin expression was not detected in any untreated
culture (not shown), even if TGF-b, another key mem-
ber of the TGF-b family, was expressed (Figure 6E).
Finally, neither the monoclonal nor the polyclonal
WT-10%B






Figure 4 The potent myotube-forming capacity of WT MDSCs in myogenic medium is decreased but still maintained under high
serum concentrations, in the presence of steady MyoD expression. (A) Representative micrographs of myotubes generated in confluent WT
MDSCs maintained for 2 weeks in myogenic medium, as evidenced by immunocytochemistry for MHC II (200×); (B) and (C) as (A), but in PM
with 20% or 10% serum (200×). (D) Representative Western blots for WT MDSCs incubated in triplicate in each of the previously mentioned
cultures in the three types of media subjected to immunodetection for MHC II (210 kDa) and MyoD (44 kDa). 10, 10% PM; 20, 20% PM; H,
myogenic medium; WT MDSC, wild-type (muscle-derived stem cell); MHC, myosin heavy chain; PM, plating medium.
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antibodies against myostatin affected myogenesis in the
WT MDSCs, as compared with the respective cultures
incubated with control IgG (not shown).
This suggests that the WT MDSC ability to form myo-
tubes is refractory to the modulation by myostatin, and
this was confirmed by transfection with the AdV Mst
cDNA construct, or alternatively, with the AdV Mst
shRNA, which also expresses b-galactosidase, which did
not inhibit or stimulate this process, although myostatin
and b-galactosidase were respectively expressed (not
shown). The suppression of myotube formation in the Mst
KO MDSCs by myostatin genetic inactivation and the lack
of response to demethylating agents suggests that this is a
complex imprinting process occurring during their embry-
ologic generation, of a different nature than the resistance
to paracrine and autocrine myostatin modulators observed
in the WT MDSCs.
Mst KO MDSCs stimulate myofiber repair in the injured
gastrocnemius of the aged mdx mouse, but the absence
of myostatin in these cells does not confer on them a
distinctive advantage over the WT MDSCs
To test the persistence of MDSCs after implantation into
the muscle, DAPI-labeled cells were implanted into the
cryolacerated gastrocnemius of the aged mdx mouse, and
frozen tissue was examined with immunocytofluorescence
for MHC II after 2 weeks. Figure 7A shows that the blue
fluorescent WT MDSC nuclei are detected in many of the
red fluorescent myofibers, and many of these nuclei are
central, as may be expected from regenerating myofibers
(yellow arrows). Other nuclei are seen in the interspersed
connective tissue among the fibers. The Mst KO MDSCs
acted similarly (Figure 7B). Although DAPI nuclear label-
ing of implanted cells may be prone to fading after long
periods of implantation, it was adequate at 2 weeks to
trace MDSC uptake and survival. However, the overlap-
ping is only suggestive and cannot conclusively show
MDSC conversion into myofibers. The MDSC implanta-
tion was then repeated into the notexin-injured muscle of
aged mdx mice, by using either WT or Mst KO cells, or
vehicle, and killing at 3 weeks for measuring myofiber
repair. Panels C and D show representative muscle tissue
sections stained with hematoxylin-eosin (HE) from mice
injected with WT MDSCs and Mst KO MDSCs, respec-
tively, where the central regenerating nuclei are visible.
When the central nuclei were counted by quantitative
image analysis, WT MDSCs significantly stimulated by
54.5% the appearance of central nuclei on hematoxylin/
Table 2 Some skeletal myogenesis-related genes are
downregulated in MDSCs by myostatin genetic
inactivation, whereas others remain unchanged
Gene Function WT KO
Spp1 Secreted phosphoprotein 1 (osteopontin) 70.8 20.3
Actc 1 a-Actin (cardiac) 39.9 6.5
Myo D1 Myogenic differentiation 1 17.5 2.7
Cadherin 15 Cadherin 15 8.7 1.7
Myf 5 Myogenic factor 5 4.2 2.7
Notch 2 Notch gene homolog 2 4.2 2.8
BMPR 2 Bone morphogenetic receptor 2 23.3 20.3
BMPR 1a Bone morphogenetic receptor 1a 8.1 10.4
BMPR 1b Bone morphogenetic receptor 1b 0.8 0.8
BMPR 4 Bone morphogenetic protein 4 2.7 2.7
IGF 1 Insulin-like growth factor 1 5.1 4.2
Jag 1 Jagged 1 2.8 3.4
Fzd 1 Frizzled homolog 1 2.7 2.8
Notch 1 Notch gene homolog 1 2.6 2.7
Notch 3 Notch gene homolog 3 2.8 2.6
RNA from the two MDSC types at 80% confluence (not undergoing
myogenesis) were treated with DNAse and submitted to DNA microarrays.
Some key myogenesis-related genes are selected. Values are relative
expression levels normalized by housekeeping genes. GAPDH expression was









































Figure 5 RT-PCR confirmation of selected differences in the
transcriptional expression of undifferentiated WT and Mst KO
MDSCs, detected with DNA microarrays. RNAs obtained from
triplicate cultures of proliferating MDSCs, consecutive to those used
for DNA microarrays in Tables 1 and 2, were subjected to RT-PCR
with specific primers spanning an intron for the number of PCR
cycles stated in parenthesis, as follows: Actc1 (30), Acta1 (30),
MyoD1 (33), Pax3 (28), and GAPDH (26). (A) Ethidium bromide-
stained agarose gels; (B) densitometry of relative band intensities
referred to housekeeping gene for the indicated numbers of PCR
cycles. Controls without cDNA were blank. *P < 0.05; ***P < 0.001.
RT-PCR, reverse transcription polymerase chain reaction; WT, wild
type; Mst KO, myostatin knockout; MDSC, muscle-derived stem cell;
DNA, deoxyribonucleic acid; RNA, ribonucleic acid; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
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eosin-stained frozen tissue sections in comparison to
control injured muscle receiving vehicle. The Mst KO
MDSCs that had failed to convert into myotubes in vitro
were now able in vivo to increase significantly by 42.4%
the number of central nuclei in the myofibers in
comparison to the vehicle-injected mice (Figure 7D).
However, this stimulation of myofiber repair did not sur-
pass the efficacy of the WT MDSCs, contrary to what
was originally expected from the absence of myostatin in























Figure 6 Myostatin and follistatin fail to modulate the myogenic differentiation of MDSCs, although the myostatin receptor is
expressed. (A-D) Confluent WT MDSCs in myogenic medium were incubated in triplicate on six-well plates for 1 week with recombinant
myostatin (B) or follistatin (C) or with no addition (A), and subjected to immunocytochemistry for MHC II (40×). The relative area occupied by
the MHC II+ myotubes was estimated by quantitative image analysis (15 fields/well/three wells) (D). Cont, control; Mst, myostatin; Fst, follistatin.
No myotubes were formed in confluent Mst KO under any treatment (not shown). (E) Western blot detection in confluent MDSCs from both
mice strains of the expression of the ActRIIb and TGF-b1, in two successive passages for each cell line. Myostatin was not detected. MDSCs,
muscle-derived stem cells; WT, wild type; Mst KO, myostatin knockout; MHC, myosin heavy chain.
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These results were supported by the fact that Mst KO
MDSCs significantly increased the expression of MCH-II
in the notexin-injured mdx aged muscle estimated by
Western blot, as compared with the vehicle-injected mus-
cle, and this was slightly more effective than WT MDSC
(Figure 8, left). It should be emphasized that this measure-
ment was conducted in the central region of the muscle,
distant from the notexin-injured sites at both ends of the
muscle used for the tissue-section studies, suggesting that
the stimulatory effect on MHC-II expression by MDSCs
may have been even higher in the injured tissue. However,
Mst KO MDSCs did not reduce ASMA expression, an
indicator of myofibroblast generation, and hence fibrosis,
whereas the WT MDSCs did decrease this expression by
23% (right).
Untreated WT mice skeletal muscles show dystrophin
expression in frozen sections, as evidenced by the sar-
colemma immunofluorescence around the myofibers
(Figure 9A), a gene that is carried by their respective


























Figure 7 Mst KO MDSCs failed to generate myotubes in vitro, but in vivo stimulate tissue repair comparable to the WT MDSCs. Aged
(10-month-old) mdx mice were used to maximize myofiber loss and lipofibrotic degeneration in the gastrocnemius. (A) Muscles were
cryoinjured, implanted with 0.5 × 106 DAPI-labeled WT MDSCs, and allowed to undergo repair for 10 days. Frozen muscle sections were stained
for MHC-II with Texas red streptavidin, and merging of blue and red fluorescence was obtained (200×). MDSC nuclei centrally located within
myofibers are indicated with yellow arrows. (B) Similar picture, but for Mst KO MDSCs. (C) Gastrocnemius injury in the aged mdx mice was
performed in the two apexes of the muscle with notexin, and muscles were injected 4 days later with saline or with 1.0 × 106 WT MDSCs or (D)
Mst KO MDSCs in saline (n = 5/group). Repair was allowed to proceed for 3 weeks. Hematoxylin/eosin staining was performed in frozen sections,
and a representative picture for each case shows myofibers from the gastrocnemius implanted with MDSCs, with arrows pointing to abundant
central nuclei (200×). (E) Quantitative image analysis of these tissue sections (WT), in comparison to tissue sections from Mst KO MDSC-
implanted mice (KO) and saline-injected controls, based on 12 fields per section, three sections per animal. ***P < 0.001. Mst KO, myostatin
knockout; MDSC, muscle-derived stem cell; WT, wild type; mdx, X chromosome-linked muscular dystrophy; DAPI, 4’, 6-diaminido-phenylindole;
MHC, myosin heavy chain; KO, knockout.
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labeling of the tissue sections. In the case of the mdx
mice that were implanted with DAPI-labeled WT
MDSCs (Figure 9C) or Mst KO MDSCs (Figure 9D),
some of the myofibers, which in the mdx muscle are
negative for dystrophin, showed a partial dystrophin+
staining of the sarcolemma in one of the areas of some
sections. Others remained dystrophin negative, as evi-
denced by comparison of the same area visualized for
dual fluorescence (Figure 9C) or with light microscopy
(Figure 9D). The overlapping of DAPI-labeled nuclei and
dystrophin+ myofibers suggests that, as in the case of Fig-
ure 7, some conversion or fusion of the implanted
MDSCs into myofibers occurs, but that this process
may be much less frequent than the stimulation of
endogenous satellite cells or stem cell differentiation or
fusion, or the spontaneous myofiber reversion.
As expected, fat infiltration is visible in the injured aged
gastrocnemius from vehicle-injected aged mdx mice,
mainly interstitially, but also as Oil Red O+ small regions
around or inside myofibers (Figure 10A and 10B). WT
MDSCs were effective in significantly reducing this fat
infiltration by 68%, and Mst KO MDSCs also induced a
decrease, although it was not significant (Figure 10C).
Discussion
To our knowledge, this is the first report testing the myo-
genic capacity of MDSCs isolated from transgenic mice


























































































Figure 8 Implanted Mst KO MDSCs stimulate more effectively than do WT MDSCs the expression of MHC-II in the muscle, but do not
reduce ASMA. (A) Western blot analysis for MHC II, ASMA, and GAPDH (reference gene) in homogenates of skeletal muscle tissue from the
central region adjacent to area examined histochemically in Figure 7C. Each lane corresponds to an individual mouse homogenate (n = 5/
group), and the three gels were run simultaneously. (B) Densitometric evaluation of the relative intensity expressed as ratios of the MCH-II or
ASMA and GAPDH bands. *P < 0.05. Mst KO, myostatin knockout; MDSC, muscle-derived stem cell; WT, wild type; MHC, myosin heavy chain;
ASMA, a-smooth muscle actin; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
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the WT MDSC, both in vitro and in the injured muscle
of the aged mdx mice in vivo. Our main findings were
(a) in contrast to WT MDSCs, Mst KO MDSCs were
unable to form myotubes in vitro, although no major dif-
ferences were found between both MDSC cultures in
terms of morphology, replication rates, expression of
most members of a subset of key embryonic-like stem
cell and other markers, and nonmyogenic multilineage
differentiation; (b) however, a fundamental difference is
that the expression of key genes in myogenesis seen in
WT MDSCs such as actc1, acta1, and myoD, was vir-
tually obliterated in Mst KO; (c) surprisingly, both types
of MDSCs were refractory in vitro to the modulation or
induction of myotube formation by well-known regula-
tors of this process, or of myofiber number in vivo, such
as demethylating agents, myostatin inhibition or overex-
pression, or follistatin, although myostatin receptors are
expressed in MDSC cultures; (d) the myofiber regenera-
tion and anti-lipofibrotic capacities of WT MDSCs were
evident even in the environment of a severely injured
mdx gastrocnemius at an age at which lipofibrotic degen-
eration is considerable; (e) in turn, these capacities,
blocked in cell culture, were recovered in Mst KO
MDSCs when they were implanted in the injured mdx
aged-muscle setting, even if not at the level expected
from the supposed paracrine effects triggered in the
MDSCs by the absence of myostatin.
It should be noted that although notexin-induced
injury is not clinically relevant for DMD, it is experi-




Figure 9 The dystrophin+ MDSCs restore some dystrophin expression in the injured mdx gastrocnemius. (A) Myofibers from the intact
gastrocnemius from the WT mouse, the source of WT MDSCs, show in a dual immunofluorescence merge all myofibers stained for dystrophin,
and nuclei stained with DAPI (Vectashield mounting medium; Vector Laboratories, Burlingame, CA, USA) (200×). (B) In other tissue sections, DAPI-
labeled implanted Mst KO MDSCs appear to have fused with the mdx myofibers, showing dystrophin+ staining in a small area. (C) A similar
picture but with WT MDSCs. (D) The same field as in (C), examined under visible light, confirming the integrity of the myofibers, including the
dystrophin- area. MDSC, muscle-derived stem cell; mdx, X chromosome-linked muscular dystrophy; WT, wild type; DAPI, 4’, 6-diaminido-
phenylindole; Mst KO, myostatin knockout.
Tsao et al. Stem Cell Research & Therapy 2013, 4:4
http://stemcellres.com/content/4/1/4
Page 14 of 19
implantation and also inducing more lipofibrotic degen-
eration both in mdx and Mst KO mice [56,57], thus
providing an adequate environment for testing the
MDSC-repair effects. The high variability in the repair
response that is often associated with notexin injection
was not observed in the current work.
The WT MDSC used here as control, fulfill all the cri-
teria that have been extensively defined as potential tools
for skeletal muscle, cardiac, and osteogenic repair on
implantation into the target organs [29,34]. In the current
work, MDSCs were isolated as the pP6 fraction by using a
modification of the extensively validated preplating proce-
dure on collagen-coated flasks and Sca1 selection, and
shown to have the expected morphology, rapid replication
for at least 50 passages, express MDSC markers such as
Sca1, CD44, and CD34, and the stem cell gene Oct 4, and
the ability to differentiate in vitro into multiple cell
lineages. The latter capability includes a robust formation
of multinucleated and branched myotubes that is assumed
to translate in vivo into their ability to donate their nuclei
to injured skeletal myofibers or most likely to stimulate
paracrinely their regeneration through paracrine trophic
effects [32-34]. This is evidenced by a much higher num-
ber of centrally located nuclei, and even some central loca-
tion of the DAPI-labeled implanted nuclei. In previous
studies, we showed that WT MDSC generate at least
smooth muscle and epithelial cells when implanted into
urogenital tissues [27,28], adding to the extensive demon-
stration of their stem cell nature [7,12,26,58] related to
their putative origin as myoendothelial stem cells in the
muscle and other tissues [59].
Another novel finding here is that WT MDSCs have
some embryonic-like stem cell features, mainly the expres-
sion of nuclear Oct 4 A, myc, LIF, and other embryonic
stem cell genes. Oct 4 is a key not only for embryonic
stem cell programming, but also for iPS generation, where
it can act virtually by itself [60]. Our MDSC cultures con-
tain some tiny rounded cells similar to the very small
embryonic-like stem cells (VSELs) described in many
adult organs [61], and other larger ones.
An important finding is the unexpected observation that
myotube formation by the WT MDSCs in vitro is refrac-
tory to modulation by agents that are well known to affect
this process, or skeletal muscle mass in vivo. The fact that
myotube formation by WT MDSCs was not influenced by
(a) demethylating agents like azacytidine that stimulate
‘stemness” in cell lines [51]; (b) downregulation or overex-
pression of myostatin, despite the detectable expression of
its receptor (ActIIb); (c) counteracting myostatin activity
by the respective antibodies or follistatin, that in vivo sti-
mulate myofiber growth [17,19,20]; poses questions related
to the role of MDSCs during normal myogenesis. A study
showing that myostatin stimulated fibroblast proliferation
in vitro and induced its differentiation into myofibroblasts,
while increasing TGF-b1 expression in C2C12 myoblasts,
did not examine MDSC differentiation [12]. The claim of
a small inhibitory effect of myostatin on the fusion index
in MDSCs [58] may indicate less fusion efficiency but
might not entirely reflect the actual effects on the number
and size of myotubes, as determined here. This question
requires further clarification in terms of the actual modu-
lation of MDSC differentiation.
It may be speculated that satellite cells rather than
MDSCs are the only myogenic progenitors during normal
myofiber growth, as opposed to repair of damaged fibers
[62]. Therefore the selected in vitro conditions may not
mimic the repair process, or alternatively, unknown in
vivo paracrine or juxtacrine modulators may modify the
response of MDSCs to the better-characterized agents
tested in this work. Another possibility is that myostatin
and other modulators investigated here would stimulate in
vivo satellite cell replication and fusion to the adjacent
myofibers to induce hypertrophy, without truly affecting
MDSC differentiation or fusion.
We are unaware of any report on the isolation or




















Figure 10 The Mst KO MDSCs are less effective than the WT
MDSCs in reducing fat deposits in the injured mdx mouse
gastrocnemius. (A) Representative picture of a positive field from
frozen-tissue sections from the untreated mdx-injured
gastrocnemius, adjacent to those shown in Figure 8D, fixed in
formalin and stained with Oil Red O, showing mostly interstitial fat
and occasional myofiber fat infiltration (200×). (B) Staining of a
representative field from sections from the muscle implanted with
WT MDSCs; the Mst KO pictures were similar, but the reduction in
staining was less marked. (C) Quantitative image analysis of the
tissue sections from the three rat groups, based on 12 fields per
tissue section and the total positive area per section (percentage),
calculated as a mean for three adjacent sections per rat, and five
mdx mice/group. *P < 0.05. Mst KO, myostatin knockout; MDSC,
muscle-derived stem cell; WT, wild type; mdx, X chromosome-linked
muscular dystrophy.
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it is also both novel and unexpected to find that these
cells obtained from the same skeletal muscles as the
WT MDSCs, by using identical procedures, and display-
ing rather similar nonmyogenic pluripotency and stem
cell-marker features, are however completely unable to
form myotubes in vitro. In fact, our prediction was that
the Mst KO MDSCs should be more myogenic than the
WT MDSCs because of the absence of the myogenic
inhibitor myostatin, The fact that Mst replenishment,
either as recombinant protein or as cDNA, does not
counteract the unexpected myogenic blockade found in
the Mst KO MDSCs, suggests speculatively that these
cells have been imprinted in the embryo by the myosta-
tin genetic inactivation through downstream pathways
that have become unresponsive to the in vitro myostatin
modulation that we explored here. This may involve
genes in other myogenic pathways whose expression
may be altered, as we observed in Mst KO MDSCs.
However, validation of this assumption requires further
investigation.
An interesting corollary is the activation of the in vitro-
suppressed myogenesis in Mst KO MDSCs, and/or their
ability to fuse with preexisting myofibers, after their
implantation into the notexin-injured mdx gastrocne-
mius. At the age selected (10 months), this muscle
experiences the considerable damage that occurs in the
diaphragm much earlier [3,4], and this is compounded by
injury. It may be speculated that the restoration of myo-
tube (myofiber) formation by Mst KO MDSCs in this set-
ting occurs by paracrine or juxtacrine modulation,
possibly of some of the key genes silenced in these cells.
Estimation of their products and proof-of-function
approaches may elucidate this issue. The fact that
although Mst KO MDSCs are able to fuse with or differ-
entiate into new myofibers, they do not increase the mus-
cle-repair process in a clearly more efficient way than do
WT MDSCs, may possibly result from the persistent
myostatin expression in the fibers that may counteract its
absence in Mst KO MDSCs. This suggests the need to
block myostatin systemically in the host muscle [63,64],
not just in the implanted MDSCs, and our findings do
not contradict the potential use of this approach
One of the genes that may be involved in the silencing of
Mst KO MDSC myogenesis in vitro and its reactivation in
vivo is the cardiac a-actin (Actc), the major striated actin in
fetal skeletal muscle and in adult cardiomyocytes, but
strongly downregulated in adult skeletal muscle to 5% of
the total striated actin [65], and whose mRNA is highly
expressed in the proliferating (nondifferentiating) WT
MDSCs but at very low level in the Mst KO MDSCs. The
same applies to the a1-actin (Acta1) mRNA, the adult pro-
tein encoding thin filaments [66]. Because actins are so
crucial for cell division, motility, cytoskeleton, and contrac-
tion, and mutations are associated with severe myopathies,
it would not be surprising that their downregulation could
cause the lack of myogenic commitment in vitro in Mst
KO.
Similarly, the striking transcriptional downregulation of
myoD, a critical early gene in skeletal myogenesis [67],
confirmed at the protein level, and of secreted phospho-
protein 1, or osteopontin, a gene mostly involved in ossifi-
cation, inflammation, and fibrosis, but postulated recently
to participate in early myogenesis and skeletal muscle
regeneration [68], may also trigger the absence of myo-
genic capacity in Mst KO. Interestingly, the fact that Pax 3
mRNA, upstream of MyoD in the myogenic signaling [69]
is expressed in Mst KO MDSCs at higher levels than in
WT MDSCs, suggests that the myogenic commitment of
Mst KO and mdx MDSC is arrested at some point
between these genes. Because a critical regulator of skele-
tal muscle development, Mef2a (myocyte enhancer factor
2a) [70], is expressed similarly in both MDSCs (as is Pax
3), albeit at very low levels, the silencing may occur at the
level of the satellite cell marker, Pax 7. Therefore, it is not
surprising that expression of a member of the cadherin
family (cadherin-15) that is involved in later stages, such
as myoblast differentiation and fusion [71], is so downre-
gulated in Mst KO MDSCs.
Conclusions
Our results show that MDSCs obtained from wild-type
and Mst KO mice lacking myostatin express Oct 4 and
other embryonic-like stem cell genes and appear similar in
most features, except for the null or poor expression in
Mst KO MDSCs of some critical early genes. These genes
encode factors critical for myogenesis and for maintaining
the integrity of myotubes and myofibers, thus possibly
leading to their inability to form myotubes in vitro. The
cross-talk of Mst KO MDSCs with myofibers and other
cell types in the host injured mdx muscle may release the
pertinent gene silencing and restore the typical myogenic
ability of the MDSCs. Although our results do not prove
the initial working hypothesis that myostatin inactivation
would enhance the myogenic capacity of MDSCs, this pos-
sibility still needs further in vivo testing by blocking myos-
tatin, not just in the implanted MDSCs, but also in the
host muscle with follistatin, shRNA, antibodies, or other
procedures. Finally, systemic muscle-targeted WT MDSC
implantation that was previously shown as a promising
approach to stimulate repair in the adult dystrophic mus-
cle [5,12,45,46], may even be effective in the setting of an
injured aged dystrophic skeletal muscle with severe bouts
of necrosis [4].
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